Aldeyra Therapeutics clinical trials we track

Check company identity source

Phase 3 12 trials

TrialDrugs studiedStatusPrimary completion
A Clinical Trial Evaluating Patients With Primary Vitreoretinal LymphomaNCT07402876ICM ADX-2191 injection, Monthly ADX-2191 injectionRecruiting2029-12Estimated
A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseaseNCT06493604Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic SolutionCompleted2025-02-27Actual
A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseaseNCT06424444Reproxalap ophthalmic solution (0.25%), Vehicle ophthalmic solutionCompleted2024-11-03Actual
A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye DiseaseNCT06389214Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic SolutionCompleted2024-06-11Actual
The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic ConjunctivitisNCT05234554Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic SolutionCompleted2023-04-22Actual
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye DiseaseNCT04735393Reproxalap Ophthalmic Solution (0.25%)Completed2022-10-11Actual
The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative VitreoretinopathyNCT04136366ADX-2191 (intravitreal methotrexate 0.8%), Standard surgical care procedureCompleted2022-06-14Actual
The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye DiseaseNCT05062330Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic SolutionCompleted2022-03-04Actual
The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.NCT04207736Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic SolutionCompleted2021-02-16Actual
The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseaseNCT03879863Reproxalap Ophthalmic Solution (0.25%) QID, Reproxalap Ophthalmic Solution (0.25%) QID to BID, Vehicle Ophthalmic Solution QID, Vehicle Ophthalmic Solution QID to BIDCompleted2019-10-04Actual
SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.NCT03131154ADX-102 Ophthalmic Solution (0.5%), Vehicle of ADX-102 Ophthalmic SolutionCompleted2019-04-19Actual
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic ConjunctivitisNCT03494504Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic SolutionCompleted2018-11-05Actual

Phase 2 / 3 1 trial

Phase 2 14 trials

TrialDrugs studiedStatusPrimary completion
A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)NCT06685692ADX-629Completed2025-06-18Actual
A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)NCT05717920ADX-629 (Open-label)Completed2023-11-21Actual
A Study in Subjects With Retinitis PigmentosaNCT05392179ADX-2191Completed2023-06-23Actual
A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic CoughNCT05392192ADX-629Completed2023-04-13Actual
A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye DiseaseNCT05424549Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic SolutionCompleted2022-05-09Actual
A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque PsoriasisNCT04908514ADX-629Completed2022-01-21Actual
A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)NCT04728711ADX-629Completed2022-01-18Actual
An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease ChamberNCT05102409Reproxalap Ophthalmic Solution (0.25%), Xiidra® (5% lifitegrast ophthalmic solution)Completed2021-10-25Actual
A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.NCT04847544ADX-629Completed2021-10-15Actual
A Clinical Trial to Assess Subjects With Dry Eye Disease.NCT04971031Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic SolutionCompleted2021-09-08Actual
A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye DiseaseNCT03916042Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID, Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BIDCompleted2019-11-22Actual
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye DiseaseNCT03404115Reproxalap Ophthalmic Solution (0.1%), Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic SolutionCompleted2018-07-11Actual
A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye SyndromeNCT03162783ADX-102 Ophthalmic Lipid Solution (0.5%), ADX-102 Ophthalmic Solution (0.1%), ADX-102 Ophthalmic Solution (0.5%)Completed2017-07-06Actual
A Safety and Activity Study of NS2 in Subjects With Allergic ConjunctivitisNCT02578914NS2 Ophthalmic Drops (0.5%), NS2 Ophthalmic Drops Vehicle (0.0%)Completed2015-12Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2026-03-16DayADX-102 Ophthalmic Solution (0.5%)Aldeyra Therapeutics, Inc. · ALDXFDA complete response letterComplete response letterNot specifiedOpen original source
Read source excerpt

{"application_number": ["NDA 216442"], "letter_date": "03/16/2026", "letter_type": "COMPLETE RESPONSE", "company_name": "Aldeyra Therapeutics, Inc.", "file_name": "CRL_NDA216442_20260316.pdf"}

First seen: 26 Sep 2026 · Evidence last checked: 26 Sep 2026

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters
A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

NCT05717920 · Aldeyra Therapeutics, Inc.

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Adverse Event (AE) Query Description: Incidence and severity of AEs Time frame: From Day 1 to Day 90. After: Measure: Number of Subjects With Serious Adverse Events Description: The proportion of subjects that experience at least one serious adverse event Time frame: The safety assessment period was approximately 15 weeks..

Check registry source
A Study in Subjects With Retinitis Pigmentosa

NCT05392179 · Aldeyra Therapeutics, Inc.

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Number of participants with adverse events (AEs). After: Measure: Number of Subjects With Serious Adverse Events.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Ocular itching evaluated by the Subject.. After: Measure: Subject-Reported Ocular Itching Score Assessed in the Allergy Chamber.

Check registry source

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 10 participants (planned). After: 4 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 31 Dec 2025. After: 18 Jun 2025.

Recruitment status changed

Before: Recruiting. After: Completed.

Check registry source